1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2015

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2015

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2015” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table Of Contents

Partnerships, Licensing, Investments and MandA Deals and Trends in Pharmaceuticals - Q4 2015
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 12
2 Pharmaceuticals and Healthcare, Global, Deal Summary, Q4 2015 16
2.1 Pharmaceuticals and Healthcare, Global, Deals Analysis, Q4 2015 16
2.2 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals, Q4 2015 19
2.3 Pharmaceuticals and Healthcare, Global, by Type, Deal Values, Q4 2015 20
2.4 Pharmaceuticals and Healthcare, Global, Top Deals, Q4 2015 21
2.4.1 Allergan and Pfizer to Combine in USD160 Billion Deal 21
2.4.2 Shire Acquires Dyax 22
2.4.3 AstraZeneca Prices Public Offering of Notes for USD6 Billion 23
2.4.4 Sanofi to Enter into Licensing Agreement with Hanmi Pharma 23
2.4.5 AstraZeneca Acquires 55% Stake in Acerta Pharma 24
3 Pharmaceuticals and Healthcare, Global, Deals Summary, by Type 25
3.1 Pharmaceuticals and Healthcare, Global, MandA, Q4 2015 25
3.1.1 Top MandA Deals in Q4 2015 26
3.1.2 Pharmaceuticals and Healthcare, Global, MandA Deals, by Therapy Area, Q4 2014 - Q4 2015 27
3.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Q4 2015 29
3.2.1 Top Initial Public Offerings in Q4 2015 30
3.2.2 Top Secondary Offerings in Q4 2015 31
3.2.3 Top PIPE Deals in Q4 2015 31
3.2.4 Pharmaceuticals and Healthcare, Global, Top IPOs Share Performance, Q4 2014-Q4 2015 31
3.2.5 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2014 - Q4 2015 32
3.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, Q4 2015 34
3.3.1 Top Venture Financing Deals in Q4 2015 35
3.3.2 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2015 36
3.3.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2015 37
3.3.4 Pharmaceuticals and Healthcare, Global, Venture Capital, by Therapy Area, Q4 2014 - Q4 2015 38
3.3.5 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Q4 2014 - Q4 2015 40
3.3.6 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, Q4 2014 - Q4 2015 42
3.4 Pharmaceuticals and Healthcare, Global, Private Equity Deals, Q4 2015 43
3.4.1 Top Private Equity Deals in Q4 2015 44
3.4.2 Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2014 - Q4 2015 45
4 Pharmaceuticals and Healthcare, Global, Partnership Deals, Q4 2015 47
4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, Q4 2015 47
4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2014 - Q4 2015 49
4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payments and Deal Values (US$ m), Q4 2015 51
4.3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2015 52
4.3.2 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2015 53
4.3.3 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2015 53
4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 54
4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2014 - Q4 2015 56
4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2014 - Q4 2015 57
4.7 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 59
5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, Q4 2015 61
5.1 Pharmaceutical and Healthcare, Global, Licensing Agreements, Q4 2015 61
5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 63
5.2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2015 64
5.2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2015 65
5.2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2015 65
5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2014 - Q4 2015 66
5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2014 - Q4 2015 68
5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2014 - Q4 2015 70
5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2014 - Q4 2015 71
5.7 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2014 - Q4 2015 73
6 Pharmaceuticals and Healthcare, Global, MandA Financial Analysis 75
6.1 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q4 2014 - Q4 2015 75
6.2 Pharmaceuticalsand Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q4 2014 - Q4 2015 77
6.3 Pharmaceuticals and Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2014 - Q4 2015 78
6.4 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2014 - Q4 2015 80
6.5 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q4 2014 - Q4 2015 82
6.6 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2014 - Q4 2015 84
7 Pharmaceuticals and Healthcare, Global, Deal Summary by Therapy Area 86
7.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, Q4 2015 86
7.1.1 Oncology - Deals of the Quarter 88
7.2 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, Q4 2015 91
7.2.1 Central Nervous System - Deals of the Quarter 93
7.3 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, Q4 2015 95
7.3.1 Infectious Disease - Deals of the Quarter 97
7.4 Pharmaceuticals and Healthcare, Global, Immunology Deals, Q4 2015 99
7.4.1 Immunology - Deals of the Quarter 101
7.5 Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals, Q4 2015 104
7.5.1 Metabolic Disorders - Deals of the Quarter 106
7.6 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, Q4 2015 108
7.6.1 Cardiovascular - Deals of the Quarter 110
7.7 Pharmaceuticals and Healthcare, Global, Gastrointestinal Deals, Q4 2015 112
7.7.1 Gastrointestinal - Deals of the Quarter 114
7.8 Pharmaceuticals and Healthcare, Global, Hematological Disorders Deals, Q4 2015 116
7.8.1 Hematological Disorders - Deals of the Quarter 117
7.9 Pharmaceuticals and Healthcare, Global, Respiratory Deals, Q4 2015 119
7.9.1 Respiratory - Deals of the Quarter 120
7.10 Pharmaceuticals and Healthcare, Global, Dermatology Deals, Q4 2015 122
7.10.1 Dermatology - Deals of the Quarter 124
8 Deal Summary by Geography 125
8.1 Pharmaceuticals and Healthcare, North America Region, Deals, Q4 2015 125
8.1.1 North America - Deals of the Quarter 127
8.2 Pharmaceuticals and Healthcare, Europe Region, Deals, Q4 2015 129
8.2.1 Europe - Deals of the Quarter 131
8.3 Pharmaceuticals and Healthcare, Asia-Pacific, Deals, Q4 2015 133
8.3.1 Asia-Pacific - Deals of the Quarter 135
8.4 Pharmaceuticals and Healthcare, Rest of the World, Deals, Q4 2015 136
8.4.1 Rest of the World - Deals of the Quarter 138
9 Pharmaceuticals and Healthcare, Global, Top Advisors 139
9.1 Pharmaceuticals and Healthcare, Global Top Financial Advisors, MandA, Q4 2014 - Q4 2015 139
9.2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Q4 2014 - Q4 2015 141
10 Appendix 143
11 Further Information 145
11.1 Methodology 145
11.2 About GlobalData 146
11.3 Disclosure information 146
11.4 Disclaimer 147

1.1 List of Tables
Table 1: Pharmaceuticals and Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 18
Table 2: Pharmaceuticals and Healthcare, Global, Number Of Deals and Deal Values (%), Q4 2015 20
Table 3: Pharmaceuticals and Healthcare, Global, Top Deals, Q4 2015 21
Table 4: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 26
Table 5: Pharmaceuticals and Healthcare, Global, Top MandA Deals, Q4 2015 26
Table 6: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q4 2014 - Q4 2015 28
Table 7: Pharmaceuticals and Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 30
Table 8: Pharmaceuticals and Healthcare, Global, Top Initial Public Offering Deals, Q4 2015 30
Table 9: Pharmaceuticals and Healthcare, Global, Top Secondary Offering Deals, Q4 2015 31
Table 10: Pharmaceuticals and Healthcare, Global, Top PIPE Deals, Q4 2015 31
Table 11: Pharmaceuticals and Healthcare, Global, Top IPOs Share Performance, Q4 2014-Q4 2015 31
Table 12: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 33
Table 13: Pharmaceuticals and Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 35
Table 14: Pharmaceuticals and Healthcare, Global, Top Venture Capital Deals, Q4 2015 35
Table 15: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q4 2015 37
Table 16: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 39
Table 17: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 41
Table 18: Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, Q4 2014 - Q4 2015 42
Table 19: Pharmaceuticals and Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 44
Table 20: Pharmaceuticals and Healthcare, Global, Top Private Equity Deals, Q4 2015 44
Table 21: Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 46
Table 22: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 48
Table 23: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 50
Table 24: Pharmaceuticals and Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 52
Table 25: Pharmaceuticals and Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), Q4 2015 52
Table 26: Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2015 53
Table 27: Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q4 2015 53
Table 28: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 55
Table 29: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q4 2014 - Q4 2015 58
Table 30: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 60
Table 31: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 62
Table 32: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 64
Table 33: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q4 2015 64
Table 34: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q4 2015 65
Table 35: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q4 2015 65
Table 36: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 67
Table 37: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront and Milestone Payment (US$ m), Q4 2014 - Q4 2015 69
Table 38: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q4 2014 - Q4 2015 72
Table 39: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront and Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 74
Table 40: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2014 - Q4 2015 76
Table 41: Pharmaceuticals and Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2014 - Q4 2015 77
Table 42: Pharmaceuticals and Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2014 - Q4 2015 79
Table 43: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q4 2014 - Q4 2015 81
Table 44: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2014 - Q4 2015 83
Table 45: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2014 - Q4 2015 85
Table 46: Pharmaceuticals and Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 87
Table 47: Pharmaceuticals and Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 92
Table 48: Pharmaceuticals and Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 96
Table 49: Pharmaceuticals and Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 100
Table 50: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 105
Table 51: Pharmaceuticals and Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 109
Table 52: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 113
Table 53: Pharmaceuticals and Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 117
Table 54: Pharmaceuticals and Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 120
Table 55: Pharmaceuticals and Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 123
Table 56: Pharmaceuticals and Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 126
Table 57: Pharmaceuticals and Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 130
Table 58: Pharmaceuticals and Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 134
Table 59: Pharmaceuticals and Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 137
Table 60: Pharmaceuticals and Healthcare, Top Financial Advisors, MandA, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 140
Table 61: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 142
Table 62: Pharmaceuticals and Healthcare, Deals' Key Financials, Global Acquisition Deals, Q4 2014-Q4 2015 143

1.2 List of Figures
Figure 1: Pharmaceuticals and Healthcare, Global, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 16
Figure 2: Pharmaceuticals and Healthcare, Global, Number Of Deals (%), Q4 2015 19
Figure 3: Pharmaceuticals and Healthcare, Global, Deal Values (%), Q4 2015 20
Figure 4: Pharmaceuticals and Healthcare, Global, MandA, Number of Deals and Deal Values (US$m), Q4 2014 - Q4 2015 25
Figure 5: Pharmaceuticals and Healthcare, Global, MandAs, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q4 2014 - Q4 2015 27
Figure 6: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 29
Figure 7: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q4 2014 - Q4 2015 32
Figure 8: Pharmaceuticals and Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 34
Figure 9: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q4 2015 36
Figure 10: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q4 2015 37
Figure 11: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2014 - Q4 2015 38
Figure 12: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 40
Figure 13: Pharmaceuticals and Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 43
Figure 14: Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2014 - Q4 2015 45
Figure 15: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 47
Figure 16: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 49
Figure 17: Pharmaceuticals and Healthcare, Global, Partnership Deals, Upfront and Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 51
Figure 18: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 54
Figure 19: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q4 2014 - Q4 2015 56
Figure 20: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q4 2014 - Q4 2015 57
Figure 21: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payment and Deal Values (US$ m), Q4 2014 - Q4 2015 59
Figure 22: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 61
Figure 23: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Upfront and Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 63
Figure 24: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 66
Figure 25: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 68
Figure 26: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q4 2014 - Q4 2015 70
Figure 27: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q4 2014 - Q4 2015 71
Figure 28: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), Q4 2014 - Q4 2015 73
Figure 29: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2014 - Q4 2015 75
Figure 30: Pharmaceuticals and Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2014 - Q4 2015 77
Figure 31: Pharmaceuticals and Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2014 - Q4 2015 78
Figure 32: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2014 - Q4 2015 80
Figure 33: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2014 - Q4 2015 82
Figure 34: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2014 - Q4 2015 84
Figure 35: Pharmaceuticals and Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 86
Figure 36: Pharmaceuticals and Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 91
Figure 37: Pharmaceuticals and Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 95
Figure 38: Pharmaceuticals and Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 99
Figure 39: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 104
Figure 40: Pharmaceuticals and Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 108
Figure 41: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 112
Figure 42: Pharmaceuticals and Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 116
Figure 43: Pharmaceuticals and Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 119
Figure 44: Pharmaceuticals and Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 122
Figure 45: Pharmaceuticals and Healthcare, North America, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 125
Figure 46: Pharmaceuticals and Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 129
Figure 47: Pharmaceuticals and Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 133
Figure 48: Pharmaceuticals and Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 136
Figure 49: Pharmaceuticals and Healthcare, Top Financial Advisors, MandA, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 139
Figure 50: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2014 - Q4 2015 141

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.